

**Remarks**

**Response to Restriction Requirement**

The Examiner divided the claims into three groups. Group I includes claims 1-34 and 43-45 drawn to an antibody IL-12 fusion protein wherein the antibody binds to a region of oncofetal fibronectin other than the ED-B region and pharmaceutical compositions containing the fusion protein. Group II includes claims 35-42 drawn to a nucleic acid, vectors and host cells encoding an antibody IL-12 fusion protein wherein the antibody binds to a region of oncofetal fibronectin other than the ED-B region and a method for producing the antibody IL-12 fusion protein. Group III includes claims 47-50 drawn to a method of treating a patient with cancer by administering an antibody IL-12 fusion protein wherein the antibody binds to a region of oncofetal fibronectin other than the ED-B region.

Applicants elect Group I including claims 1-34 and 43-45 without traverse. Groups I and III are related as product and process of use.

**Amendment to the Claims**

Claims 35-42 were canceled without prejudice or disclaimer. Applicants reserve the right to pursue these claims in divisional or continuation applications. Once the product claim is found allowable, withdrawn process claims will be rejoined.

U.S.S.N. 10/596,997

I.A. Filed: January 5, 2005

**AMENDMENT AND RESPONSE TO TO RESTRICTION REQUIREMENT**

Allowance of claims 1-34 and 43-45 and 47-50 is respectfully solicited.

Respectfully submitted,

/Charles Vorndran, Ph.D., J.D./  
Charles Vorndran, Ph.D., J.D.  
Reg. No. 45,315

Date: May 29, 2009

PABST PATENT GROUP LLP  
1545 Peachtree Street, NE  
Suite 320  
Atlanta, Georgia 30309  
(404) 879-2151  
(404) 879-2160 (Facsimile)